|
Since 28 February 2005, Intercell AG has been included in the
prime market of the Vienna Stock Exchange. Intercell AG is a
biotechnology company focused on developing, manufacturing and
commercializing prophylactic and therapeutic vaccines against infectious
diseases.
About Intercell AG
Through proprietary research and development programs and technologies,
the company develops novel prophylactic vaccines that protect the human
body against future infections and therapeutic vaccines that enhance the
human immune system’s response to existing infections. The Company’s
unique position is based on the combination of antigens and immunizers (adjuvants)
derived from its proprietary technology platforms and its in-house GMP
facilities.
Intercell AG has two late stage product candidates in development. IC 51,
Intercell’s most advanced product candidate, is a prophylactic vaccine
against the Japanese Encephalitis virus. This vaccine candidate is
expected to commence Phase III clinical in mid-2005, a market launch is
estimated for 2007.
IC 41, Intercell’s second most advanced product candidate is a therapeutic
vaccine against the Hepatitis C virus, which completed a phase II clinical
trial in 2004. The Hepatitis C vaccine is also in a parallel phase II
clinical trial in combination with the current standard therapy and is
scheduled to enter additional clinical trials in 2005.
Intercell has a robust pre-clinical pipeline of five internally developed
product candidates which address a high unmet medical need in attractive
markets. The company aims to develop some of these in-house and others
through additional strategic partnerships.
The company´s core technologies utilize innovative processes to identify
antigens that are recognized by the human immune system. In addition,
Intercell develops proprietary adjuvants, or “immunizers,” which stimulate
the human immune system’s response to an antigen and enhance its ability
to fight and destroy the associated pathogen. Intercell selectively
in-licenses product candidates for development when those product
candidates serve its strategic interests.
Intercell’s technologies have been endorsed by collaborative agreements
with a number of global pharmaceutical companies, including Aventis
Pasteur, Merck&Co., Inc., Scigen and the Statens Serum Institut.
For more information please visit:
www.intercell.com and
www.wienerborse.at |
